Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value in Oncology
Palliative Care Program Eases Patient Symptoms and Hospital Costs
By
Chase Doyle
Value in Oncology
November 2016, Vol 7, No 10
San Francisco, CA—In addition to improving quality of care and patient satisfaction, palliative care can also save hospitals millions of dollars, according to a study presented by lead investigator Sarina Isenberg, PhD candidate, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. The study’s final analysis showed that expanded patient access to palliative care demonstrated substantial savings to the Johns Hopkins Hospital and Health System and could lead to approximately $20 million in savings in 5 years, said Ms Isenberg at the 2016 Palliative Care in Oncology Symposium.
Read Article
The Challenges of Paying for Cancer Care Will Only Get Worse
By
Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—The issues surrounding the cost of cancer care are large and looming in today’s healthcare landscape, but these problems are nothing compared to what is coming, according to Amitabh Chandra, PhD, Director of Health Policy Research, Harvard Kennedy School of Government, Cambridge, MA, who spoke at the War on Cancer forum organized by
The Economist
.
Read Article
The Growing Shift Toward Value-Based Drug Pricing
By
Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—Drug pricing in the pharmaceutical industry came under scrutiny at the recent War on Cancer forum organized by
The Economist
. An expert panel discussed the disassociation between the actual benefits of cancer drugs and their prices.
Read Article
DCIS Score Not Cost-Effective in Selecting Patients for Adjuvant Radiation
By
Wayne Kuznar
Value in Oncology
October 2016, Vol 7, No 9
Read Article
Hematologic Cancers Among the Most Costly Malignancies to Treat
By
Alice Goodman
Hematologic Cancers
,
Value in Oncology
October 2016, Vol 7, No 9
Read Article
Value Assessments of Metastatic Colorectal Cancer Therapies Continue to Focus on Cost
By
Charles Bankhead
Value in Oncology
October 2016, Vol 7, No 9
Read Article
New Anticancer Drugs Increase Costs but Prolong Life
By
Laura Morgan
Value in Oncology
October 2016, Vol 7, No 9
A study by David H. Howard, PhD, Associate Professor, Department of Health Policy and Management, Emory University, Atlanta, and colleagues demonstrated that although anticancer drugs are associated with increased expenses, they were also accompanied by considerable survival benefits across different cancer types (Howard DH, et al. Health Aff [Millwood]. 2016;35:1581-1587)
Read Article
Hematopoietic-Cell Transplants Require Substantial All-Cause Healthcare Resource Utilization
By
Jessica Miller
Value in Oncology
October 2016, Vol 7, No 9
Read Article
Referring Radical Prostatectomies to High-Volume Providers Could Save Millions
By
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
A new study of the geographic distribution of cancer surgeries in the Medicare population has shown that performing radical prostatectomies in high-volume centers leads to improved outcomes and reduced costs of care. Referring patients to a high-volume provider within 100 miles could save >$20 million annually, according to data presented at the 2016 American Society of Clinical Oncology annual meeting and published just before the meeting.
Read Article
Assessing the Cost–Benefit of Immune Checkpoint Inhibitors
By
Chase Doyle
Value in Oncology
September 2016, Vol 7, No 8
Although immune checkpoint inhibitors can significantly extend survival of patients with metastatic disease, more than 50% of the patients who use them have serious, grade 3 to grade 5 adverse events. These toxicities comprise a considerable proportion of the total number of immune checkpoint inhibitors, especially those that target PD-1, said Neil T. Mason, MBA, Personalized Medicine Strategist, Moffitt Cancer Center, Tampa, FL, who presented his study results at a poster session at the 2016 American Society of Clinical Oncology annual meeting.
Read Article
Page 3 of 7
1
2
3
4
5
6
7
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma